Home > Publications Database > Comparing loss of individual fragile X proteins suggests strong links to cellular senescence and aging. > print

001     281808
005     20251113111203.0
024 7 _ |a 10.1007/s00018-025-05898-0
|2 doi
024 7 _ |a pmid:41117937
|2 pmid
024 7 _ |a 1420-682X
|2 ISSN
024 7 _ |a 0014-4754
|2 ISSN
024 7 _ |a 1420-9071
|2 ISSN
037 _ _ |a DZNE-2025-01194
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Menge, Sonja
|0 0000-0003-3445-2753
|b 0
245 _ _ |a Comparing loss of individual fragile X proteins suggests strong links to cellular senescence and aging.
260 _ _ |a Cham (ZG)
|c 2025
|b Springer International Publishing AG
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763028477_32671
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Members of the fragile X protein (FXP) family (FMR1, FXR1 and FXR2) are differentially expressed in most types of cancer and major neurodegenerative diseases. While increased expression of FXR1 in cancer has been linked to senescence evasion and consequently tumor initiation and progression, decreased expression of FXPs in neurodegeneration may contribute to pathogenic protein aggregation and death of vulnerable neurons. However, due the causal role in fragile x syndrome, most data are available about loss of FMR1 in neurons while functions of FXR1 and especially FXR2 remain largely unexplored. To address this knowledge gap, and to directly compare functions of the FXPs, we used proteomics of CRISPR/Cas9 edited HAP1 cells carrying knockouts of the individual FXPs for identification of cellular mechanisms associated with these proteins. Further exploration of proteomic findings suggests roles of the FXPs in ribosome biogenesis, autophagy and mitochondrial health linked to organismal aging, and cellular senescence. Validation of FXP induced defects relevant for neurodegenerative diseases in neuroblastoma cell line SH-SY5Y upon FXP knockdown revealed high cell type specificity of individual FXP functions. Overall, we provide a comprehensive overview and comparison of cellular mechanisms related to the individual FXPs, as well as starting points for further studying this protein family in respective cell types of FXP associated diseases, and in aging in general.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Amyotrophic lateral sclerosis
|2 Other
650 _ 7 |a Fragile x syndrome
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a Protein aggregation
|2 Other
650 _ 7 |a Fragile X Mental Retardation Protein
|0 139135-51-6
|2 NLM Chemicals
650 _ 7 |a RNA-Binding Proteins
|2 NLM Chemicals
650 _ 7 |a FMR1 protein, human
|2 NLM Chemicals
650 _ 7 |a FXR1 protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cellular Senescence: genetics
|2 MeSH
650 _ 2 |a Fragile X Mental Retardation Protein: genetics
|2 MeSH
650 _ 2 |a Fragile X Mental Retardation Protein: metabolism
|2 MeSH
650 _ 2 |a Aging: genetics
|2 MeSH
650 _ 2 |a Aging: metabolism
|2 MeSH
650 _ 2 |a RNA-Binding Proteins: metabolism
|2 MeSH
650 _ 2 |a RNA-Binding Proteins: genetics
|2 MeSH
650 _ 2 |a CRISPR-Cas Systems
|2 MeSH
650 _ 2 |a Autophagy
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
650 _ 2 |a Proteomics: methods
|2 MeSH
650 _ 2 |a Mitochondria: metabolism
|2 MeSH
650 _ 2 |a Fragile X Syndrome: metabolism
|2 MeSH
650 _ 2 |a Fragile X Syndrome: genetics
|2 MeSH
650 _ 2 |a Fragile X Syndrome: pathology
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: metabolism
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: genetics
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: pathology
|2 MeSH
700 1 _ |a Segura, Inmaculada
|0 0000-0003-1849-5569
|b 1
700 1 _ |a Hartmann, Max
|b 2
700 1 _ |a Decker, Lorena
|b 3
700 1 _ |a Kiran, Selin
|0 P:(DE-2719)9001513
|b 4
700 1 _ |a Danzer, Karin M
|0 P:(DE-2719)9001513
|b 5
|u dzne
700 1 _ |a Iben, Sebastian
|b 6
700 1 _ |a Harbauer, Angelika B
|0 0000-0002-4568-9003
|b 7
700 1 _ |a Oeckl, Patrick
|0 P:(DE-2719)9001560
|b 8
700 1 _ |a Freischmidt, Axel
|0 P:(DE-2719)9001054
|b 9
773 _ _ |a 10.1007/s00018-025-05898-0
|g Vol. 82, no. 1, p. 358
|0 PERI:(DE-600)1458497-9
|n 1
|p 358
|t Cellular and molecular life sciences
|v 82
|y 2025
|x 1420-682X
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP1.xlsx
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP2.xlsx
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP3.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281808/files/DZNE-2025-01194.pdf
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP1.csv
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP1.ods
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP1.xls
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP2.csv
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP2.ods
856 4 _ |u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP2.xls
856 4 _ |x pdfa
|u https://pub.dzne.de/record/281808/files/DZNE-2025-01194%20SUP3.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281808/files/DZNE-2025-01194.pdf?subformat=pdfa
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9001513
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001513
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9001560
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-19
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
920 1 _ |0 I:(DE-2719)5000072
|k AG Danzer
|l Mechanisms of Propagation
|x 0
920 1 _ |0 I:(DE-2719)5000073
|k AG Öckl
|l Translational Mass Spectrometry and Biomarker Research
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000072
980 _ _ |a I:(DE-2719)5000073
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21